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Abstract
Background: Chronic kidney disease (CKD) is known to be associated with several co-occurring conditions. We
aimed at exploring multimorbidity patterns associated with CKD, as well as the impact of physical performance and
CKD severity on them in a population of older outpatients.
Methods: Our series consisted of 2252 patients enrolled in the Screening of CKD among Older People across
Europe multicenter observational study. Hypertension, stroke, transient ischemic attack, cancer, hip fracture,
osteoporosis, Parkinson’s disease, asthma, chronic obstructive pulmonary disease, congestive heart failure, angina,
myocardial infarction, atrial fibrillation, anemia, CKD (defined as GFR < 60, < 45 or < 30 ml/min/1.73 m2), cognitive
impairment, depression, hearing impairment and vision impairment were included in the analyses. Physical
performance was assessed by the Short Physical Performance Battery (SPPB) and used as stratification variable. Pairs
of co-occurring diseases were analyzed by logistic regression. Patterns of multimorbidity were investigated by
hierarchical cluster analysis.
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Results: CKD was among the most frequently observed conditions and it was rarely observed without any other
co-occurring disease. CKD was significantly associated with hypertension, anemia, heart failure, atrial fibrillation,
myocardial infarction and hip fracture. When stratifying by SPPB, CKD was also significantly associated with vision
impairment in SPPB = 5–8 group, and hearing impairment in SPPB = 0–4 group. Cluster analysis individuated two
main clusters, one including CKD, hypertension and sensory impairments, and the second including all other
conditions. Stratifying by SPPB, CKD contribute to a cluster including diabetes, anemia, osteoporosis, hypertension
and sensory impairments in the SPPB = 0–4 group. When defining CKD as eGFR< 45 or 30 ml/min/1.73 m2, the
strength of the association of CKD with hypertension, sensory impairments, osteoporosis, anemia and CHF
increased together with CKD severity in pairs analysis. Severe CKD (eGFR< 30 ml/min/1.73 m2) contributed to a wide
cluster including cardiovascular, respiratory and neurologic diseases, as well as osteoporosis, hip fracture and cancer.
Conclusions: CKD and its severity may contribute significantly to specific multimorbidity patterns, at least based on
the cluster analysis. Physical performance as assessed by SPPB may be associated with not negligible changes in
both co-occurring pairs and multimorbidity clusters.
Trial registration: The SCOPE study is registered at clinicaltrials.gov (NCT02691546).
Keywords: Chronic kidney disease, Multimorbidity, Short physical performance battery, Older
Background
The progressive aging of the population in industrialized
countries is accompanied by a dramatic increase in the
prevalence of multiple chronic diseases [1]. Traditionally,
research has embraced the comorbidity conceptual
framework, i.e. a framework which identifies an index
disease and focuses on the probability of having other
(secondary) diseases [2]. In an attempt to meet the com-
plex problems posed by older patients with multiple
chronic diseases, the attention has progressively shifted
from the comorbidity to the multimorbidity conceptual
framework. In this approach the co-occurrence of two
or more diseases is taken into consideration without
identifying an index disease [3, 4]. From the clinical
point of view, the multimorbidity concept tends to push
geriatric medicine towards an individual-oriented and no
longer disease-oriented approach. Several different ana-
lytic approaches can be used to investigate multimorbid-
ity. Studies explored multimorbidity by applying
different methods (e.g. prevalence figures, conditional
count, logistic regression models, cluster or network
analysis and data mining techniques) to disease variables
in different populations, and provided convincing evi-
dence that chronic diseases may combine each other not
simply due to chance [5–10].
Chronic kidney disease (CKD) is among the most fre-
quent chronic conditions observed among older patients,
and it dramatically impacts health status and survival in
the general population, as well as in older populations
[11–14]. Although CKD is known to be associated with
several long lasting conditions, such as hypertension,
diabetes, heart failure, anemia and osteoporosis, studies
investigating patterns of multimorbidity including CKD
provided heterogeneous results. Formiga et al. [6]
showed that CKD may contribute to a multimorbidity
cluster including cardio- and cerebro-vascular disease,
atrial fibrillation, diabetes mellitus and visual impair-
ment. More recently, CKD was found to contribute to a
larger cluster including cardiovascular diseases (excluded
coronary artery disease), endocrine abnormalities, neuro-
logical disorders including dementia, respiratory and
muscle-skeletal diseases, infections and sensory impair-
ment [10]. Thus, multimorbidity patterns involving CKD
are worth of testing in other different populations.
Additionally, data about the impact of potentially rele-
vant stratification variables on patterns of multimorbid-
ity are very limited. Current evidence suggests that age,
sex, and race/ethnicity may be associated with small but
not negligible changes in multimorbidity patterns [10].
However, whether patterns of multimorbidity may
change as a function of physical performance has not
been investigated until now, despite the bidirectional
interplay of multimorbidity and functional decline is
more and more recognized as a crucial step in the as-
sessment of health and care needs of older complex pa-
tients [15].
Finally, CKD severity may also affect multimorbidity
patterns. Indeed, many of CKD-related concordant co-
morbidities, such as anemia, osteoporosis and heart fail-
ure, are known to be associated with the severity of
CKD [16].
By including a detailed collection of data about diag-
noses and comprehensive geriatric assessment including
short physical performance battery (SPPB) [17], the
Screening for CKD among Older People across Europe
(SCOPE) study represents a valuable opportunity to ex-
plore multimorbidity patterns as well as the impact of
physical performance and CKD severity on them in a
Corsonello et al. BMC Geriatrics 2020, 20(Suppl 1):350 Page 2 of 12
population of older community-dwelling people. These
were the main objectives of our study.
Methods
The SCOPE study (European Grant Agreement no.
436849), is a multicenter 2-year prospective cohort study
involving patients older than 75 years attending geriatric
and nephrology outpatient services in participating insti-
tutions in Austria, Germany, Israel, Italy, the
Netherlands, Poland and Spain. Methods of the SCOPE
study have been extensively described elsewhere [18].
Briefly, all patients attending the outpatient services (7
geriatric and internal medicine and 2 nephrology ser-
vices) at participating centers from August 2016 to
August 2018 were asked to participate. Only patients
signing a written informed consent entered the study.
Age greater or equal to 75 years was the only inclusion
criteria, the exclusion criteria were: end-stage renal dis-
ease or dialysis at time of enrollment; history of solid
organ or bone marrow transplantation; active malig-
nancy within 24months prior to screening or metastatic
cancer; life expectancy less than 6 months (based on the
judgment of the study physician after careful medical
history collection and diagnoses emerging from examin-
ation of clinical documentation exhibited); severe cogni-
tive impairment (Mini Mental State Examination < 10);
any medical or other reason (e.g. known or suspected
patients’ inability to comply with the protocol proced-
ure) in the judgement of the investigators, that the pa-
tient was unsuitable for the study; unwilling to provide
consent and limited possibility to attend follow-up visits.
The study protocol was approved by ethics committees
at all participating institutions, and complies with the
Declaration of Helsinki and Good Clinical Practice
Guidelines. Only baseline data are used in the present
study.
Overall, 2461 patients were initially enrolled in the
study. Of them, 209 patients were excluded from this
study because of incomplete baseline data, thus leaving a
final sample of 2252 patients to be included in the
analysis.
Study variables
Diagnoses were ascertained by the study physician by
clinical history and physical examination. Physicians
asked the participants to show all clinical records and
prescription forms or drug containers of the drugs used.
The following diagnoses were included in the analysis:
hypertension, stroke, transient ischemic attack (TIA),
cancer, hip fracture, osteoporosis, Parkinson’s disease,
asthma, chronic obstructive pulmonary disease (COPD),
congestive heart failure (CHF), angina, myocardial in-
farction, atrial fibrillation. Chronic kidney disease was
defined on the basis of estimated glomerular filtration
rate (eGFR) < 60ml/min/1.73 m2. eGFR was calculated
by creatinine-based Berlin Initiative Study (BIS) equation
[19]. Such equation has been developed to be used in
older people and has been externally validated against
gold-standard measured GFR [20, 21]. Cognitive impair-
ment was defined as age- and education-adjusted Mini
Mental State Examination (MMSE) score less than 24
[22]. Depression was ascertained on the basis of Geriat-
ric Depression Scale (GDS) score greater than 5 [23].
Vision and hearing impairment were coded on a scale
from 0 (adequate) to 4 (no vision/hearing present) [24],
and patients with at least mild deficit (scoring 1 or
more) were considered as impaired. Anemia was defined
as a hemoglobin level less than 13 g/dL in men and less
than 12 g/dL in women. Multimorbidity was defined as
the co-occurrence of two or more diseases.
Further variables included in the analysis were age,
sex, and physical performance. Physical performance
was measured by SPPB [17]. The SPPB includes gait
speed (usual time to walk 4 m), five chair-stands test
(time to rise from a chair and return to the seated pos-
ition five times without using arms), and balance test
(ability to stand with the feet together in the side-by-
side, semi-tandem, and tandem positions). A score from
0 to 4 was assigned to performance on each task. Indi-
viduals received a score of 0 for each task they were un-
able to complete. Summing the three individual
categorical scores, a summary performance score was
created for each participant (range, 0–12), with higher
scores indicating better lower body function. SPPB score
was stratified using the following cut-offs: 9–12, best
performance; 5–8, intermediate performance; 0–4, worst
performance [17].
Analytic approach
First, descriptive analysis of the study population grouped
according to SPPB score was provided. Data were re-
ported as mean ± SD for continuous variables and number
(percentage) for categorical ones. Chi-square test was used
to analyze categorical variables, while ANOVA one way
was used for continuous ones. For each chronic disease in-
cluded in the analysis, its prevalence with and without co-
occurring disease(s) was estimated. The expected preva-
lence of disease pairs involving CKD was computed and
compared with the observed co-prevalence. To confirm
the results of the pairs analysis and to control for possible
confounders, logistic regression models were conducted
to analyze the association between each pair of co-
occurring diseases. This analysis was adjusted for age, sex,
and all of the other diseases. To analyze different patterns
of associative multimorbidity, without any a priori hypoth-
esis, we used a hierarchical agglomerative clustering ap-
proach to create dendrograms. A binary distance measure
(squared euclidean distance) was used to produce the
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distance matrix resulting in more distinctive clusters com-
pared with other proximity measures. For dendrograms
analysis we used the Ward method as previously reported
[10] to find compact clusters and minimizes the variance
within clusters [25]. In order to investigate the impact of
physical performance on multimorbidity patterns, analyses
were repeated after stratification by SPPB score. Finally, in
order to investigate the impact of CKD severity on
patterns of multimorbidity, disease pairs and cluster
analyses were repeated by using two additional eGFR
thresholds, < 45 and < 30ml/min/1.73m2, to define CKD.
Statistical analysis was carried out by using SPSS for
Win V23.0 statistical software package (SPSS Inc.,
Chicago, IL, USA).
Results
Descriptive analysis
General characteristics of the study population are
reported in Table 1. Age ranged between 75 and 96
years, and more than half of enrolled patients were
women. CKD was among the most frequently observed
conditions (66.0%), together with hypertension and sen-
sory impairments (Table 1). CKD occurred without any
other co-occurring disease in only 0.9% of participants.
The corresponding figures for other diagnoses were 1.5%
for hypertension, 1% for vision impairment, 0.4% for
hearing impairment. All other diagnoses were also rarely
present without any associated disease.
When stratifying population by physical performance,
SPPB = 9–12 was observed in 1391(61.8%) patients,
while 614 patients (27.3%) had SPPB = 5–8, and 247 pa-
tients (11.0%) had SPPB = 0–4. This latter group in-
cluded only a minority of patients (n = 24) not able to do
any SPPB tasks and scoring 0 at physical performance
assessment. Patients with lower SPPB scores were older
and more frequently women (Table 1). Additionally,
almost all diagnoses were more prevalent among physic-
ally impaired patients (Table 1).
Patterns of multimorbdity and physical performance
Observed and expected prevalence of the most fre-
quently co-occurring pairs of diseases and their
Table 1 General characteristics and prevalence of selected diseases among SCOPE study participants (N = 2252) and their
distribution across physical performance status
All
patients
N = 2252
SPPB score P
9–12
N = 1391
5–8
N = 614
0–4
N = 247
Age, years 80.3 ± 4.1 79.6 ± 3.7 81.2 ± 4.4 82.4 ± 4.7 < 0.001
Sex, women 1254 (55.7) 698 (50.2) 381 (62.1) 175 (70.9) < 0.001
Hypertension 1729 (76.8) 997 (71.7) 509 (82.9) 223 (90.3) < 0.001
CKD 1487 (66.0) 871 (62.6) 415 (67.6) 201 (81.4) < 0.001
Vision impairment 1299 (57.7) 758 (54.5) 370 (60.3) 171 (69.2) < 0.001
Hearing impairment 1165 (51.7) 661 (47.5) 348 (56.7) 156 (63.2) < 0.001
Osteoporosis 687 (30.5) 324 (23.3) 243 (39.6) 120 (48.6) < 0.001
Diabetes 566 (25.1) 280 (20.1) 188 (30.6) 98 (39.7) < 0.001
Anemia 476 (21.1) 228 (16.4) 150 (24.4) 98 (39.7) < 0.001
Cancer 388 (17.2) 234 (16.8) 104 (16.9) 50 (20.2) 0.413
CHF 373 (16.6) 187 (13.4) 119 (19.4) 67 (27.1) < 0.001
Atrial fibrillation 344 (15.3) 159 (11.4) 116 (18.9) 69 (27.9) < 0.001
Depression 316 (14.0) 134 (9.6) 113 (18.4) 69 (27.9) < 0.001
COPD 266 (11.8) 149 (10.7) 86 (14) 31 (12.6) 0.101
Myocardial infarction 217 (9.6) 112 (8.1) 65 (10.6) 40 (16.2) < 0.001
TIA 196 (8.7) 104 (7.5) 64 (10.4) 28 (11.3) 0.029
Cognitive impairment 165 (7.3) 71 (5.1) 59 (9.6) 35 (14.2) < 0.001
Angina 133 (5.9) 72 (5.2) 39 (6.4) 22 (8.9) 0.062
Stroke 131 (5.8) 59 (4.2) 45 (7.3) 27 (10.9) < 0.001
Asthma 124 (5.5) 73 (5.2) 30 (4.9) 21 (8.5) 0.087
Hip fracture 111 (4.9) 32 (2.3) 51 (8.3) 28 (11.3) < 0.001
Parkinson 45 (2.0) 11 (0.8) 17 (2.8) 17 (6.9) < 0.001
Data are mean ± SD or number of cases (percentage)
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association are shown in Table 2. The most frequent co-
occurring pairs involving CKD were those with hyper-
tension, sensory impairments, osteoporosis, diabetes and
anemia. After adjusting for age, sex and all other dis-
eases included in the analyses, CKD was significantly as-
sociated with hypertension, anemia, CHF, atrial
fibrillation, myocardial infarction and hip fracture, while
near significant associations were observed with hearing
impairment, diabetes and cancer (Table 2). It is worth not-
ing that 89.4% of diabetic patients were also affected by
hypertension, and the association between CKD and dia-
betes became significant when removing hypertension from
the fully adjusted model (OR = 1.36, 95%CI = 1.08–1.71).
When stratifying pairs analysis by physical perform-
ance, CKD was significantly associated with
hypertension (OR = 1.66, 95%CI = 1.28–2.14), CHF
(OR = 1.63, 95%CI = 1.09–2.43), atrial fibrillation (OR =
1.82, 95%CI = 1.18–2.79) and hip fracture (OR = 0.34,
95%CI = 0.15–0.76) among patients with SPPB score =
9–12. At variance, the significant co-occurring pairs in-
volving CKD were those with hypertension (OR = 2.79,
95%CI = 1.72–4.52), CHF (OR = 2.39, 95%CI = 1.27–
4.47), anemia (OR = 3.68, 95%CI = 2.09–6.48) and vision
impairment (OR = 1.50, 95%CI = 1.02–2.20) among pa-
tients with SPPB = 5–8. Finally, significant co-occurring
pairs among patients with SPPB = 0–4 were those in-
volving hypertension (OR = 3.54, 95%CI = 1.21–10.4),
anemia (OR = 2.10, 95%CI = 1.03–4.68) and hearing im-
pairment (OR = 2.20, 95%CI = 1.02–4.93).
Finally, patterns of multimorbidity from cluster ana-
lysis are reported in Fig. 1. Overall, cluster analysis indi-
viduated two main clusters, one including CKD,
hypertension and sensory impairments, and the second
including all other conditions. When stratifying this
analysis by SPPB, these patterns were substantially
confirmed among patients with SPPB = 9–12 or SPPB =
5–8. At variance, the pattern of multimorbidity involving
CKD was clearly different among patients with lowest
level of physical performance where a sub-cluster includ-
ing diabetes, anemia and osteoporosis appeared near to
the one including hypertension, CKD and sensory im-
pairments. When repeating this latter analysis after ex-
cluding 24 patients scoring 0 at SPPB assessment, the
dendrogram remained unchanged (not shown).
Patterns of multimorbidity and CKD severity
When defining CKD as eGFR< 45 or 30ml/min/1.73 m2,
the strength of the association of CKD with hyperten-
sion, sensory impairments, osteoporosis, anemia and
CHF increased together with CKD severity (Table 3). Fi-
nally, patterns of multimorbidity also changed signifi-
cantly in relation to CKD severity. Indeed, eGFR< 45ml/
min/1.73 m2 contributed to a sub-cluster including
anemia, diabetes and osteoporosis, while severe CKD
Table 2 Observed and expected prevalence of co-occurring pairs of diseases involving CKD in the whole study population (N = 2252)
Co-occurring pairs Cases
n
Observed
%
Expected
%
Obs/
Exp
ratio
Adjusted for age and sex Fully adjusted
OR 95%CI OR 95%CI
CKD Hypertension 1224 54.4 50.7 1.07 2.30 1.87–2.82 1.90 1.53–2.36
CKD Vision impairment 880 39.1 38.1 1.03 1.25 1.04–1.50 1.06 0.87–1.29
CKD Hearing impairment 822 36.5 34.2 1.07 1.37 1.15–1.64 1.20 0.98–1.46
CKD Osteoporosis 449 19.9 20.1 0.99 1.02 0.83–1.25 0.95 0.76–1.18
CKD Diabetes 420 18.7 16.6 1.12 1.63 1.31–2.03 1.22 0.97–1.55
Anemia CKD 388 17.2 13.9 1.24 2.26 1.75–2.92 1.95 1.49–2.54
CHF CKD 305 13.5 10.9 1.24 2.47 1.86–3.29 1.73 1.27–2.36
Cancer CKD 282 12.5 11.4 1.10 1.36 1.06–1.75 1.27 0.98–1.64
Atrial fibrillation CKD 276 12.3 10.1 1.22 2.07 1.55–2.75 1.57 1.15–2.13
CKD Depression 212 9.4 9.3 1.02 1.06 0.81–1.37 0.93 0.71–1.23
CKD COPD 202 9.0 7.8 1.15 1.58 1.16–2.14 1.26 0.91–1.74
CKD Myocardial infarction 182 8.1 6.4 1.27 2.46 1.68–3.61 1.75 1.17–2.62
CKD TIA 136 6.0 5.7 1.05 1.07 0.77–1.49 0.88 0.62–1.24
CKD Cognitive impairment 120 5.3 4.8 1.10 1.15 0.80–1.67 1.06 0.72–1.56
CKD Stroke 98 4.4 3.8 1.13 1.37 0.90–2.07 1.11 0.72–1.72
Angina CKD 94 4.2 3.9 1.07 1.17 0.79–1.74 0.72 0.46–1.11
Asthma CKD 81 3.6 3.6 0.99 1.03 0.69–1.52 0.85 0.56–1.28
CKD Hip fracture 65 2.9 3.3 0.89 0.57 0.38–0.86 0.59 0.38–0.91
CKD Parkinson 31 1.4 1.3 1.04 0.94 0.49–1.82 0.83 0.42–1.67
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defined as eGFR< 30 ml/min/1.73 m2 contributed to a
wide cluster including cardiovascular, respiratory and
neurologic diseases, as well as osteoporosis, hip fracture
and cancer Fig. 2.
Discussion
Findings from the present study suggests that CKD sig-
nificantly contributes to multimorbidity patterns in a
population of older outpatients. Additionally, simple
count of disease may hide several important information
otherwise obtained by the analysis of most relevant pairs
of co-occurring disease or disease clusters. Indeed, as
already reported in former studies [5, 6, 26, 27] the oc-
currence of individual conditions without any associated
disease was rarely observed in our study population. Fi-
nally, and in a relevant way, our study also suggests that
multimorbidity patterns may change as a function of
physical performance as assessed by SPPB.
The most relevant co-occurring pairs involving CKD
observed in our study where those with hypertension,
anemia, CHF, atrial fibrillation, myocardial infarction,
hip fracture, and to a lesser extent hearing impairment,
diabetes and cancer. The weak association between CKD
and diabetes was not surprising given that almost all dia-
betic patients also had high blood pressure in our study
and removing hypertension from the multivariable
model made statistically significant such association in
pairs analysis. Additionally, it is worth noting that after
Fig. 1 Dendrograms resulting from clusters analysis testing the distribution and aggregation of chronic diseases in the whole study population
and after stratifying by SPPB
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Table 3 Observed and expected prevalence of co-occurring pairs of diseases involving CKD defined as eGFR< 45 (upper panel) or < 30
ml/min/1.73m2 (lower panel)
Co-occurring pairs Cases
n
Observed
%
Expected
%
Obs/
Exp
ratio
Adjusted for age and sex Fully adjusted
OR 95%CI OR 95%CI
CKD = eGFR < 45ml/min/1.73m2
CKD Hypertension 509 22.6 19.0 1.2 3.87 2.82–5.30 3.01 2.14–4.20
CKD Vision impairment 359 15.9 14.3 1.1 1.56 1.26–1.91 1.21 0.95–1.53
CKD Hearing impairment 360 16.0 12.8 1.2 1.79 1.46–2.19 1.48 1.17–1.87
CKD Osteoporosis 186 8.3 7.6 1.1 1.38 1.10–1.73 1.22 0.94–1.56
CKD Diabetes 211 9.4 6.2 1.5 2.31 1.86–2.86 1.62 1.27–2.04
Anemia CKD 245 10.9 5.2 2.1 4.21 3.36–5.26 3.64 2.86–4.61
CHF CKD 149 6.6 4.1 1.6 2.21 1.73–2.81 1.34 1.00–1.79
Cancer CKD 121 5.4 4.3 1.3 1.36 1.06–1.74 1.21 0.92–1.58
Atrial fibrillation CKD 124 5.5 3.8 1.5 1.64 1.27–2.11 1.19 0.88–1.59
CKD Depression 78 3.5 3.5 1.0 0.99 0.74–1.32 0.79 0.57–1.08
CKD COPD 95 4.2 2.9 1.4 1.65 1.24–2.18 1.31 0.95–1.80
CKD Myocardial infarction 107 4.8 2.4 2.0 2.89 2.14–3.89 2.00 1.43–2.78
CKD TIA 58 2.6 2.2 1.2 1.15 0.82–1.61 0.95 0.65–1.39
CKD Cognitive impairment 46 2.0 1.8 1.1 0.98 0.67–1.41 0.90 0.60–1.35
CKD Stroke 46 2.0 1.4 1.4 1.49 1.01–2.18 1.21 0.78–1.85
Angina CKD 49 2.2 1.5 1.5 1.74 1.19–2.55 0.98 0.62–1.52
Asthma CKD 32 1.4 1.4 1.0 1.15 0.74–1.76 0.93 0.58–1.49
CKD Hip fracture 24 1.1 1.2 0.9 0.66 0.40–1.06 0.67 0.39–1.15
CKD Parkinson 14 0.6 0.5 1.2 1.15 0.59–2.22 0.80 0.38–1.66
CKD = eGFR < 30ml/min/1.73m2
CKD Hypertension 135 6.0 4.8 1.3 8.44 3.43–20.7 5.73 2.29–14.3
CKD Vision impairment 107 4.8 3.6 1.3 2.71 1.81–4.06 1.79 1.13–2.81
CKD Hearing impairment 103 4.6 3.2 1.4 2.49 1.68–3.66 1.69 1.09–2.61
CKD Osteoporosis 64 2.8 1.9 1.5 2.79 1.90–4.08 2.22 1.46–3.34
CKD Diabetes 51 2.3 1.6 1.5 1.69 1.17–2.42 1.16 0.77–1.71
Anemia CKD 83 3.7 1.3 2.8 5.53 3.83–7.96 4.64 3.16–6.79
CHF CKD 49 2.2 1.0 2.1 2.70 1.86–3.91 1.77 1.14–2.73
Cancer CKD 34 1.5 1.1 1.4 1.45 0.96–2.17 1.26 0.81–1.93
Atrial fibrillation CKD 32 1.4 0.9 1.5 1.46 0.95–2.22 0.96 0.59–1.55
CKD Depression 19 0.8 0.9 0.9 1.00 0.60–1.65 0.81 0.46–1.38
CKD COPD 25 1.1 0.7 1.5 1.45 0.91–2.30 0.97 0.56–1.65
CKD Myocardial infarction 28 1.2 0.6 2.0 2.05 1.30–3.21 1.49 0.89–2.50
CKD TIA 11 0.5 0.5 0.9 0.78 0.40–1.47 0.64 0.31–1.28
CKD Cognitive impairment 7 0.3 0.5 0.7 0.57 0.25–1.25 0.54 0.23–1.23
CKD Stroke 13 0.6 0.4 1.7 1.52 0.82–2.78 1.35 0.68–2.65
Angina CKD 8 0.4 0.4 1.1 0.88 0.41–1.84 0.46 0.20–1.03
Asthma CKD 7 0.3 0.3 0.9 0.99 0.44–2.16 0.87 0.38–1.99
CKD Hip fracture 7 0.3 0.3 1.0 0.93 0.41–2.07 0.83 0.34–1.98
CKD Parkinson 4 0.2 0.1 1.6 1.27 0.44–3.63 0.85 0.27–2.63
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stratification by SPPB score other significant pairs
emerged among patients with SPPB = 5–8 (vision im-
pairment) and SPPB = 0–4 (hearing impairment). Thus,
it seems that a simple physical performance test, already
known to predict mobility disability, ADL dependency,
rehospitalization and death [28–31], may also help to
describe patients with somewhat different profiles of co-
occurring pairs of diseases.
While the association between CKD and cardiovascu-
lar diseases, anemia, diabetes and mineral bone disease
(including fractures) is well recognized and extensively
addressed in clinical guidelines where specific recom-
mendations are provided for these conditions [32], the
combination of CKD with cancer and sensory impair-
ments deserves to be discussed. Chronic kidney disease
(CKD) and cancer are strictly related each other. Cancer
can cause CKD either directly or indirectly through the
adverse effects of treatments. Conversely, CKD may rep-
resent a relevant risk factor for cancer [33]. Indeed,
though the increased risk of death observed among CKD
patients is mainly attributable to cardiovascular disease,
the incidence of cancer is also increased [16]. Cancer
can affect the kidney either as glomerular lesions or as a
result of the toxic effects of medication or radiation with
acute (thrombotic microangiopathy, acute kidney injury,
interstitial nephropathies among others) or chronic pro-
cesses (worsening of CKD after nephrectomy due to
renal cancer, interstitial fibrosis, water and electrolytes
disorders) [34]. It is worth noting that we only consid-
ered history of cancer in our study, while patients carry-
ing active malignancies during the last 24 months before
enrollment were excluded. Nevertheless, older cancer
survivors may be more likely to develop frailty or wors-
ening of the health status, and such association may be
especially relevant among individuals with a recent (< 10
years) history of cancer [35].
Given the mean age of enrolled patients, the associ-
ation between CKD and sensory impairment may be
simply related to older age independent of kidney func-
tion. However, several potential mechanisms may
underly such association. Hearing loss was found to be
highly prevalent among CKD patients [36, 37], and in-
creasing serum creatinine or blood pressure was found
associated with increasing hearing threshold [38]. Several
similarities between cochlea and kidney can be observed,
including membranous structures, the central role of
ciliated epithelial cells, and tubular organization [39]. In
experimental uremic animals, a significant decrease in
cochlear Na + −K + -ATPase activity resulted in hearing
impairment [40]. Additionally, ototoxic medications may
also contribute to the observed association. For example,
furosemide may affect ionic gradients between the endo-
lymph and perilymph thus altering endocochlear poten-
tial and leading to cochlear dysfunction [41]. The
association between CKD and vision impairment was
also reported to be highly prevalent in CKD patients. A
population study involving 10,033 adults aged 40–80
years showed that the prevalence of vision impairment
and ocular disease were significantly higher in partici-
pants with (36.1 and 84.7%) compared to those without
CKD (12.9 and 54.3%, both p < 0.001) [42]. Diabetic ret-
inopathy and age-related macular degeneration are most
consistently associated with CKD [43]. It is worth noting
that mechanisms underlying CKD, such as vascular re-
modeling, endothelial dysfunction, atherosclerosis, in-
flammation, and oxidative stress are also involved in the
development of many eye diseases. Besides diabetes and
hypertension, metabolic disorders associated with CKD,
Fig. 2 Dendrograms resulting from clusters analysis testing the distribution and aggregation of chronic diseases in the study population using
two different eGFR threshold to define CKD (< 45 or < 30ml/min/1.73m2)
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such as oxidative stress, uremia, anemia, as well as spe-
cific treatment, such as steroids and dialysis may be also
involved [43]. Despite this bulk of evidence, screening
for vision and hearing impairment is not currently rec-
ommended in CKD clinical guidelines and our findings
suggest for its potential usefulness in this vulnerable
population.
Cluster analysis provided quietly consistent results
showing that CKD may contribute to a cluster of multi-
morbidity including hypertension and sensory impair-
ments in the whole study population. These findings are
somewhat different from those reported in former stud-
ies and characteristics of population, as well as the list of
diagnoses included in the analysis likely account for
these differences. Marengoni et al. identified five major
clusters (two linked to vascular diseases with hyperten-
sion and heart failure playing the main role and the
others to dementia, diabetes mellitus, and malignancy)
in a population of 1099 community-dwelling people
aged 77 or more. However, CKD was not included in
the list of diagnoses [5]. In the study by Formiga et al.
[6], the list of diagnoses was very similar to that in our
study and four main clusters were identified in a popula-
tion of 328 oldest old people aged 85 or more. CKD
contributed to a multimorbidity cluster including atrial
fibrillation, heart failure, visual impairment, stroke,
hypertension and diabetes mellitus [6]. More recently,
Zemedikun et al. [10] identified 3 main multimorbidity
clusters with CKD contributing to the wide cluster in-
cluding cardiovascular diseases (excluded coronary ar-
tery disease), endocrine abnormalities, neurological
disorders including dementia, respiratory and muscle-
skeletal diseases, infections and sensory impairment.
However, at variance from our study their analysis was
carried out in a population younger than 70 years [10].
Interestingly, when stratifying analysis according to
physical performance, the cluster including CKD was
“enriched” by a sub-cluster including anemia and osteo-
porosis (i.e. two well-known complications of CKD,
namely CKD-related anemia and CKD-Mineral Bone
Disease (CKD-MBD)) and diabetes (i.e. a leading cause
of CKD) among patients with lowest SPPB scores. Thus,
both co-occurring pairs and clustering of diseases may
change as a function of SPPB among older people in the
present study, and SPPB is among the most useful frailty
tools for the identification of patients that may benefit
from interventions aimed at improving functional cap-
acity in primary care settings [44]. Our findings are in
keeping with current guidelines stating that frailty and
sensory impairments are very relevant items when inves-
tigating multimorbidity, while defining multimorbidity
by simple counts of health conditions may be misleading
[45]. Indeed, current evidence suggests that frailty and
multimorbidity are strictly related each other in older
adults [46, 47]. Additionally, physical performance
assessed by gait speed and grip strength was recently
found significantly associated with both the development
of multimorbidity and worsening pre-existing multimor-
bidity, with evidence of a dose–response relationship
[48]. Our results further strengthen the need to assess
physical function in clinical practice and to establish
specific function-oriented interventions able to reduce
the burden of multimorbidity and related negative
outcomes.
Finally, this is the first study including CKD severity in
the analysis of multimorbidity patterns. Indeed, CKD se-
verity was not considered in former multimorbidity
studies [6, 10]. Besides confirming that the strength of
the association between CKD and selected complica-
tions, i.e. hypertension, sensory impairments, osteopor-
osis, anemia and CHF may increase together with CKD
severity [16], our study adds to current knowledge by
showing that the complexity of multimorbidity cluster
including CKD may also change in relation to CKD se-
verity. These findings suggest that severity of individual
diseases should be taken into consideration in future
studies of multimorbidity among older complex patients.
Limitations of our study deserve to be mentioned. The
cross-sectional design did not allow to investigate path-
ways leading to multimorbidity and the prognostic im-
pact of specific multimorbidity patterns. Additionally,
the list of diagnoses included in the analysis could not
be considered exhaustive. However, we used a list of
diagnoses very similar to that already used in studies in-
vestigating multimorbidity patterns. Nevertheless, the
prevalence of individual diseases and that of individual
diagnoses with multimorbidity was somewhat higher in
the SCOPE study population compared to former stud-
ies [5, 6, 10], likely because we enrolled older people at-
tending outpatients services in participating institutions
with an extensive assessment and a complete analysis of
clinical documentation exhibited by patients and care-
givers, while former studies were population-based [5, 6,
10]. Our study did not include the assessment of severity
of each individual disease other than CKD and findings
from CKD severity analysis suggest that disease severity
may represent a relevant confounder. The very rare oc-
currence of selected diagnoses without multimorbidity
prevented us to explore differences between patients
with and without multimorbidity. Finally, we need to
recognize that while the analysis of co-occurring pairs
may have an immediate clinical relevance, results ob-
tained by hierarchical cluster analysis of diagnoses is less
easy to be translated to clinical practice. Nevertheless,
these exploratory data may represent a sound scientific
basis for future studies on the clinical characterization of
patient clusters and/or groups carrying specific multi-
morbidity patterns involving CKD. This study also has
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important strengths, including the enrollment of a real-
world European population of older community-
dwelling people and the opportunity to investigate the
impact of objectively measured physical performance on
patterns of multimorbidity.
Conclusions
CKD contributes significantly to multimorbidity in a
population of older outpatients and it was rarely ob-
served without any co-occurring disease. The most sig-
nificant co-occurring pairs involving CKD included
hypertension, anemia, CHF, atrial fibrillation, myocardial
infarction, hip fracture, and to a lesser extent hearing
impairment, diabetes and cancer. Cluster analysis
showed that CKD may cluster with hypertension and
sensory impairments. Physical performance as assessed
by SPPB may be associated with not negligible changes
in both co-occurring pairs and multimorbidity clusters.
These findings strengthen the need of assessing physical
performance and investigating interventions targeting
physical function among complex multimorbid patients
in an attempt to improve outcomes and reduce costs as-
sociated with multimorbidity. Finally, CKD severity may
significantly affect patterns of multimorbidity, which
suggests that disease severity should be further investi-
gated in multimorbidity studies.
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